Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Expert Council Approves RET Proto-Oncogene Testing

This article was originally published in PharmAsia News

Executive Summary

The advanced medical expert council at the Ministry of Health, Labor and Welfare approved rearranged-during-transfection proto-oncogene testing to identify medullary thyroid cancer. The testing is to diagnose whether the medullary thyroid cancer is inherited or not, which then determines corresponding treatments. The use of the genetic assay allows earlier and more definitive identification and clinical management of those with a familial risk for medullary thyroid cancer. The approval allows the testing to be covered by medical insurance. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts